Table 6:

Multivariable model of dexamethasone as the main predictor of delirium incidence in adults aged ≥ 65 years admitted to acute care hospitals with COVID-19 in wave 2 of the COVID-19 pandemic^*

Variable	Unadjusted OR	Adjusted OR^†
Dexamethasone use	2.11 (1.32–3.46)	1.38 (0.77–2.50)
Remdesivir use	0.93 (0.53–1.58)	1.56 (0.80–3.04)
Tocilizumab use	2.19 (0.74–6.53)	2.53 (0.73–9.24)
Age, yr^‡	1.31 (1.17–1.48)	1.21 (1.04–1.40)
Dementia	4.99 (2.86–8.89)	3.25 (1.67–6.45)
Clinical Frailty Scale score	1.53 (1.32–1.79)	1.53 (1.24–1.91)
Intensive care unit admission	2.94 (1.82–4.77)	6.82 (3.65–13.11)

Note: OR = odds ratio.
↵* Number of records in model: 395; Hosmer–Lemeshow test: p = 0.57; C statistic: 0.800.
↵† Adjusted for remdesivir use, tocilizumab use, age, dementia, Clinical Frailty Scale and intensive care unit admission.
↵‡ Each 5-year increase.